Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Tandem Diabetes Care arrives at the end of September with short sellers adding pressure, analysts cutting targets, and the stock down 27% from where it printed Q2 results in August.
Short interest is the clearest signal of mounting scepticism. At 18.9% of free float, it has climbed 9% over the past week and nearly 19% over the past month, a build that tracks almost exactly with the stock's slide from roughly $21 to $16.57. The FINRA fortnightly count, settled to September 15, put shares short at 12.47 million with a days-to-cover of 7.89, making any sharp reversal structurally difficult to sustain. The ORTEX short score of 59.5 keeps TNDM firmly in the elevated-conviction-short bracket, yet the borrow market itself tells a different story: availability is extremely loose at 1,080%, meaning there are more than ten shares available to borrow for every one already lent out. Cost to borrow has barely moved, holding near 0.52% annually. Short sellers face no squeeze pressure from the lending market. The position is being built into ample supply, which makes this a conviction trade rather than a mechanical or technical accumulation.
Options have edged more defensive over the week, though not dramatically so. The put/call ratio closed at 0.58 on Tuesday after spiking to 0.75 on Monday, both above the 20-day mean of 0.47 and at roughly 1.4 standard deviations above it. The 52-week high on PCR is 1.17, so current hedging is elevated but not at any extreme. The options picture corroborates a cautious but not panicked market.
The Street's direction of travel is clearly lower on targets, though most firms still hold positive ratings. Citigroup's Joanne Wuensch cut her target today to $20 from $24 while staying Neutral. Truist's Richard Newitter trimmed to $28 from $31 on September 24, keeping his Buy. Several other firms, including UBS, Mizuho, and Deutsche Bank, have moved targets lower through the summer. The mean price target across the Street is $28.35, roughly 71% above the current price of $16.57, but that gap reflects the recent slide rather than fresh bullishness. William Blair initiated with Outperform in August without a target, adding another name to the bull side.
The bull and bear cases are genuinely in tension here. Bulls point to the t:slim X2 and Mobi pump portfolio, a pharmacy-channel shift that the company argues lifts customer lifetime value from around $8,000 to $17,000, an over-150,000 out-of-US patient base representing a meaningful renewal opportunity, and a Mobi Tubeless patch pump slated for late 2026 FDA approval. Full-year guidance of $1.065 to $1.085 billion in revenue with a 56 to 57% gross margin implies a company that has turned a corner on execution. Bears focus on the near-term revenue distortion from the shift to a Pay/Go pharmacy model, where upfront shipments carry $0 of revenue and conversion is still early. The stock trades at roughly 1.3x EV/Sales, and the P/B multiple has fallen around 1.8 points over the past month. The EV/EBITDA of 12.9x is heading lower alongside the price, but profitability remains thin, with a deeply negative P/E reflecting ongoing losses.
Ownership gives some context on who is sitting with the pain. BlackRock added 892,000 shares through August to hold 16.6% of shares. Vanguard entities collectively hold another 11% or so, adding steadily. Sessa Capital, a smaller active manager, holds 7.3% and also added shares through June. First Light Asset Management added over two million shares to reach 4.9%, the largest percentage increase among the top holders. These are not fast-money flows. Voya Financial is notable on the other side, having cut its stake from 6.3% to 0.2% per its August filing, one of the sharper disclosed exits in the register. All 13D/G stakes are as last disclosed and holders can fall below 5% without a further filing.
The next earnings date is November 4, and the most recent print, Q2 in August, produced a one-day move of plus 14.2% and a five-day follow-through of plus 18.1%. The quarter before that saw a one-day fall of 7%. History shows TNDM can move sharply in either direction around results. With short interest near 19% of float, a seven-week wait until the print, and analysts still trimming targets despite broadly constructive ratings, the key question into November will be whether the pharmacy-channel transition is tracking ahead or behind management's own timeline.
See the live data behind this article on ORTEX.
Open TNDM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
